Two PE funds managed by China International Capital Corporation (CICC) will exit Jiangyin Tianjiang Pharmaceutical as China Traditional Chinese Medicine (China TCM) buys a majority stake...
Exits | 29 Jan 2015 |
Southeast Asia-focused healthcare investor Quadria Capital, which is expected to close its latest fund in the next two months, has taken a minority stake in Indonesian drug manufacturer Soho Global Health.
Southeast Asia | 27 Jan 2015 |
Legend Capital has led a Series C round of funding worth $100 million for Innovent Biologics, a Chinese biopharmaceutical company.
Healthcare | 27 Jan 2015 |
Japan’s Mitsui Global Investment and Dolby Family Ventures have together invested $12 million in cloud-based, clinical study software start-up goBalto.
North Asia | 22 Jan 2015 |
Meinian Onehealth Healthcare, China’s largest private provider of healthcare check-up services and a portfolio company of The Carlyle Group, has invested in industry rival Ciming Health Checkup Management Group.
Greater China | 20 Jan 2015 |
Temasek Holdings - an investment arm of the Singapore government - has acquired a 17.74% stake in Global Health, which operates the Mendanta super specialty hospital in Gurgaon, India.
Healthcare | 20 Jan 2015 |
Solvanix, an Australian early-stage biotech company that has developed a technology for improving drug stability, has received A$2 million ($1.6 million) in seed funding from the Medical Research Commercialization Fund (MRCF).
Healthcare | 19 Jan 2015 |
UK development finance institution (DFI) CDC Group has invested $48 million in Indian multi-specialty healthcare provider Narayana Hrudayalaya Hospitals (NH) in return for a small minority stake.
South Asia | 15 Jan 2015 |
Yunfeng Capital and other investors have agreed to invest up to RMB10 billion ($1.6 billion) in Chinese drug maker Guangzhou Baiyushan Pharmaceutical Holdings.
Greater China | 14 Jan 2015 |
China-focused biotech investor BVCF has led an $8 million Series A round of funding for DiaCarta, a US-based firm that develops test kits for detecting cancer.
Healthcare | 12 Jan 2015 |
Ally Bridge Group, a healthcare-focused PE firm, has led a $25 million Series B round of funding for Hua Medicine, a Shanghai-based clinical-stage biotech company.
Greater China | 09 Jan 2015 |
To Homer Sun, CIO at Morgan Stanley Private Equity Asia (MSPEA), the current climate in China’s hospital services space is reminiscent of pharmaceuticals circa 2008. Government policy was pushing the industry towards consolidation and MSPEA capitalized,...
Healthcare | 07 Jan 2015 |
Australian biopharmaceutical start-up EnGeneIC has received $10 million in a Series B round of funding led by Boston-based healthcare specialist GRT Capital Partners.
Venture | 07 Jan 2015 |
Morgan Stanley Private Equity Asia (MSPEA) has teamed up with Sihuan Pharmaceuticals – one of its portfolio companies – and that company’s chairman to invest RMB1.24 billion ($200 million) in two Chinese hospitals.
Healthcare | 02 Jan 2015 |
A consortium including Hony Capital, Goldman Sachs and Canada Pension Plan Investment Board (CPPIB) has agreed to invest $610 million in two medical device subsidiaries owned by Neusoft Corporation, a Chinese IT services provider.
Greater China | 12 Dec 2014 |
Updating your subscription status
The outlook for the Australasian market is positive as a record number of IPO exits have provided strong returns for investors and has proven that PE can outperform listed equities and compete with global divestment figures. Fundraising in terms of dollar value has been high but the number of PE funds successfully raising new commitments has declined as investors flock to the best in class.
This is an intriguing time for Australasian PE as the industry continues to mature. GPs must evolve, diversify and display skills to drive value in a low-growth environment and justify future commitments when competing on a global state by achieving world-class results from current deals and exits.
4-6 March 2015, The Westin, Sydney
The AVCJ Indonesia Forum is back for a fourth year! Mark your calendars now and join us on March 24th, 2015 in Jakarta at Indonesia's longest running, largest and most prestigious industry gathering.
The market is relatively optimistic as a new government that is viewed favourable to a balanced investment arena is introduced and we see an increase in deal activity. The hopes for a flourishing PE market amid the euphoria of 2012 has not yet been realised but the potential is still present and now may well be the time for the country to take off in its own right and increase its reputation as THE hot market in Southeast Asia.
24 March 2015, Grand Hyatt, Jakarta